Top

Published in:

01-04-2010 | Review Paper

AIDS Denialism and Public Health Practice

Authors: Pride Chigwedere, M. Essex

Published in: AIDS and Behavior | Issue 2/2010

Abstract

In this paper, we respond to AIDS denialist arguments that HIV does not cause AIDS, that antiretroviral drugs are not useful, and that there is no evidence of large-scale deaths from AIDS, and discuss the key implications of the relationship between AIDS denialism and public health practice. We provide a brief history of how the cause of AIDS was investigated, of how HIV fulfills Koch’s postulates and Sir Bradford Hill’s criteria for causation, and of the inconsistencies in alternatives offered by denialists. We highlight clinical trials as the standard for assessing efficacy of drugs, rather than anecdotal cases or discussions of mechanism of action, and show the unanimous data demonstrating antiretroviral drug efficacy. We then show how statistics on mortality and indices such as crude death rate, life expectancy, child mortality, and population growth are consistent with the high mortality from AIDS, and expose the weakness of statistics from death notification, quoted by denialists. Last we emphasize that when denialism influences public health practice as in South Africa, the consequences are disastrous. We argue for accountability for the loss of hundreds of thousands of lives, the need to reform public health practice to include standards and accountability, and the particular need for honesty and peer review in situations that impact public health policy.

Science Guardian. Awards in Washington for Duesberg and Farber. Available at: <http://www.scienceguardian.com/blog/whistleblower-awards-in-washington-for-duesberg-and-farber.htm>. Accessed 2009 Sept 5.

For a summary citing original studies, see [10].

See http://duesberg.com/faq.html. Accessed 2009 Nov 25.

See FDA’s Center for Drug Evaluation and Research. Available at:<http://www.fda.gov/Drugs/default.htm>. Accessed 08/06/2009.

Example from ref. 3: Duesberg quotes a Lancet study (May MT et al. 2006;368:451–458) that ARVs have “not translated into a decrease in mortality” when the full statement reads “Virological response after starting HAART improved over calendar years, but such improvement has not translated into a decrease in mortality.” The authors are comparing 1998 mortality on HAART with 1995–1996 and 2002–2003 on HAART, not ARVs versus nothing.

US Census Bureau International Database. Available at: <http://www.census.gov/ipc/www/idb/country.php>. Accessed 2009 Aug 9.

http://www.avert.org/safricastats.htm. Accessed 2009 Aug 9.

Joint United Nations Programme on HIV/AIDS (UNAIDS) Reference Group on Estimates, Modelling and Projections. Available at: <http://www.epidem.org/>. Accessed 2009 Aug 9.

UNAIDS. Report on the Global HIV/AIDS Epidemic. Geneva: UNAIDS; 2000, 2002, 2004, 2006. In the 2006 report, UNAIDS suggests that its earlier modeling could have overestimated the prevalence of AIDS and death statistics. We used the estimates from the 2006 report for both 2005 and 2003 estimates, and the 2002 report for 2001 estimates.

Health Systems Trust, South Africa. Available at: <http://www.hst.org.za/healthstats/178/data>. Accessed 2009 Aug 9.

Health Systems Trust, South Africa. Available at: http://www.healthlink.org.za/healthstats/86/data>. Accessed 2009 Aug 9.

Quoted by BBC News, 2008 Nov 7. Available at: <http://news.bbc.co.uk/2/hi/africa/7716128.stm>. Accessed 2009 Aug 7.

Quoted in The Guardian, 2001 Jun 12. Available at: <http://www.guardian.co.uk/world/2001/jun/12/aids.chrismcgreal>. Accessed 2009 Aug 7.

International Criminal Court. Available at: <http://www.icc-cpi.int/about/Official_Journal.html>. Accessed 2007 Nov 20.

Chigwedere P, Seage GR 3rd, Gruskin S, Lee TH, Essex M. Estimating the lost benefits of antiretroviral drug use in South Africa. J Acquir Immune Defic Syndr. 2008;49:410–5.PubMed

Nattrass N. AIDS and the scientific governance of medicine in post-apartheid South Africa. African Affairs. 2008;107:157–76.

Duesberg PH, Nicholson JM, Rasnick D, Fiala C, Bauer HH. HIV-AIDS hypothesis out of touch with South African AIDS—a new perspective. Med Hypotheses. 2009; Epub ahead of print (withdrawn).

Lenzer J. AIDS “dissident” seeks redemption… and a cure for cancer. Discover. 2008;29(6):44–50.

Duesberg P. HIV is not the cause of AIDS. Science. 1988;241(4865):514, 517. Other of Duesberg’s writings available at: <http://www.duesberg.com/>. Accessed 2009 Nov 17.

Baleta A. South Africa’s AIDS care thrown into confusion. Lancet. 1999;354:1711.PubMed

Cohen J. South Africa. AIDS researchers decry Mbeki’s views on HIV. Science. 2000;288:590–1.PubMed

Horton R. Mbeki defiant about South African HIV/AIDS strategy. Lancet. 2000;356(9225):225.PubMed

Masland T, King P. Flirting with strange ideas. Mbeki reaches out to a controversial AIDS researcher. Newsweek. 2000;135(16):36.PubMed

10.

Essex M, Mboup S. The etiology of AIDS. In: Essex M, Mboup S, Kanki P, Marlink R, Tlou S, editors. AIDS in Africa. New York: Kluwer Academic/Plenum; 2002. p. 1–10.

11.

Gottlieb MS, Schroff R, Schanker HM, et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: evidence of a new acquired cellular immunodeficiency. N Engl J Med. 1981;305(24):1425–31.PubMed

12.

Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med. 1981;305(24):1431–8.PubMedCrossRef

13.

Siegal FP, Lopez C, Hammer GS, et al. Severe acquired immunodeficiency in male homosexuals, manifested by chronic perianal ulcerative herpes simplex lesions. N Engl J Med. 1981;305(24):1439–44.PubMed

14.

Epidemiological aspects of the current outbreak of Kaposi’s sarcoma and opportunistic infections. N Engl J Med. 1982; 306: 248–52.

15.

Masur H, Michelis MA, Wormser GP, et al. Opportunistic infection in previously healthy women. Initial manifestations of a community-acquired cellular immunodeficiency. Ann Intern Med. 1982;97(4):533–9.PubMed

16.

Davis KC, Horsburgh CR Jr, Hasiba U, Schocket AL, Kirkpatrick CH. Acquired immunodeficiency syndrome in a patient with hemophilia. Ann Intern Med. 1983;98(3):284–6.PubMed

17.

Poon MC, Landay A, Prasthofer EF, Stagno S. Acquired immunodeficiency syndrome with Pneumocystis carinii pneumonia and Mycobacterium avium-intracellulare infection in a previously healthy patient with classic hemophilia. Clinical, immunologic, and virologic findings. Ann Intern Med. 1983;98(3):287–90.PubMed

18.

Jett JR, Kuritsky JN, Katzmann JA, Homburger HA. Acquired immunodeficiency syndrome associated with blood-product transfusions. Ann Intern Med. 1983;99(5):621–4.PubMed

19.

Curran JW, Lawrence DN, Jaffe H, et al. Acquired immunodeficiency syndrome (AIDS) associated with transfusions. N Engl J Med. 1984;310(2):69–75.PubMedCrossRef

20.

Rubinstein A, Sicklick M, Gupta A, et al. Acquired immunodeficiency with reversed T4/T8 ratios in infants born to promiscuous and drug-addicted mothers. JAMA. 1983;249(17):2350–6.PubMed

21.

Francis DP, Curran JW, Essex M. Epidemic acquired immune deficiency syndrome: epidemiologic evidence for a transmissible agent. J Natl Cancer Inst. 1983;71(1):1–4.PubMed

22.

Durack DT. Opportunistic infections and Kaposi’s sarcoma in homosexual men. N Engl J Med. 1981;305(24):1465–7.PubMedCrossRef

23.

Brennan RO, Durack DT. Gay compromise syndrome. Lancet. 1981;2(8259):1338–9.PubMed

24.

Kitchen LW, Barin F, Sullivan JL, et al. Aetiology of AIDS—antibodies to human T-cell leukaemia virus (type III) in haemophiliacs. Nature. 1984;312(5992):367–9.PubMed

25.

Sarngadharan MG, Popovic M, Bruch L, Schüpbach J, Gallo RC. Antibodies reactive with human T-lymphotropic retroviruses (HTLV-III) in the serum of patients with AIDS. Science. 1984;224(4648):506–8.PubMed

26.

Barre-Sinoussi F, Chermann JC, Rey F, et al. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):868–71.PubMed

27.

Gallo RC, Sarin PS, Gelmann EP, et al. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science. 1983;220(4599):865–7.PubMed

28.

Aschengrau A, Seage GR. Essentials of epidemiology in public health. 2nd ed. Sudbury, MA: Jones & Bartlett; 2008. p. 383–410.

29.

Knight DC, Schrotter G. Robert Koch: father of bacteriology. New York: Franklin Watts; 1961.

30.

Ambrose Z, KewalRamani VN, Bieniasz PD, Hatziioannou T. HIV/AIDS: in search of an animal model. Trends Biotechnol. 2007;25(8):333–7.PubMed

31.

Cohen J. Fulfilling Koch’s postulates. Science. 1994;266:1647.

32.

O’Brien SJ, Goedert JJ. HIV causes AIDS: Koch’s postulates fulfilled. Curr Opin Immunol. 1996;8(5):613–8.PubMed

33.

Hill AB. The environment and disease: association or causation? Proc R Soc Med. 1965;58:295–300.PubMed

34.

Schechter MT, Craib KJ, Gelmon KA, Montaner JS, Le TN, O’Shaughnessy MV. HIV-1 and the aetiology of AIDS. Lancet. 1993;341(8846):658–9.PubMed

35.

Darby SC, Ewart DW, Giangrande PL, Dolin PJ, Spooner RJ, Rizza CR. Mortality before and after HIV infection in the complete UK population of haemophiliacs. UK Haemophilia Centre Directors’ Organisation. Nature. 1995;377(6544):79–82.PubMed

36.

Biggar RJ. AIDS incubation in 1891 HIV seroconverters from different exposure groups. International Registry of Seroconverters. AIDS. 1990;4(11):1059–66.PubMed

37.

Prins M, Veugelers PJ. Comparison of progression and non-progression in injecting drug users and homosexual men with documented dates of HIV-1 seroconversion. European Seroconverter Study and the Tricontinental Seroconverter Study. AIDS. 1997;11(5):621–31.PubMed

38.

Engels EA, Rosenberg PS, O’Brien TR, Goedert JJ. Plasma HIV viral load in patients with hemophilia and late-stage HIV disease: a measure of current immune suppression. Multicenter Hemophilia Cohort Study. Ann Intern Med. 1999;131(4):256–64.PubMed

39.

Mellors JW, Rinaldo CR Jr, Gupta P, White RM, Todd JA, Kingsley LA. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science. 1996;272(5265):1167–70.PubMed

40.

Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med. 1997;337:725–33.PubMed

41.

Katzenstein DA, Hammer SM, Hughes MD, et al. The relation of virologic and immunologic markers to clinical outcomes after nucleoside therapy in HIV-infected adults with 200 to 500 CD4 cells per cubic millimeter. AIDS Clinical Trials Group Study 175 Virology Study Team. N Engl J Med. 1996;335(15):1091–8.PubMed

42.

O’Brien WA, Hartigan PM, Martin D, et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med. 1996;334(7):426–31.PubMed

43.

Levy JA. HIV and the pathogenesis of AIDS. 3rd ed. Washington: ASM Press; 2007.

44.

Knipe DM, Howley PM, editors. Fields’ virology. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2007.

45.

Cohen J. Duesberg and critics agree: hemophilia is the best test. Science. 1994;266:1645–6.PubMed

46.

Horton R. Will Duesberg now concede defeat? Lancet. 1995;346(8976):656.PubMed

47.

Duesberg PH. Is HIV the cause of AIDS? Lancet. 1995;346(8986):1371–2.PubMed

48.

Blattner W, Gallo RC, Temin HM. HIV causes AIDS. Science. 1988;241(4865):515–6.PubMed

49.

Pachl C, Todd JA, Kern DG, et al. Rapid and precise quantification of HIV-1 RNA in plasma using a branched DNA signal amplification assay. J Acquir Immune Defic Syndr Hum Retrovirol. 1995;8(5):446–54.PubMed

50.

Henrard DR, Phillips JF, Muenz LR, et al. Natural history of HIV-1 cell-free viremia. JAMA. 1995;274(7):554–8.PubMed

51.

Coffin JM. HIV population dynamics in vivo: implications for genetic variation, pathogenesis, and therapy. Science. 1995;267(5197):483–9.PubMed

52.

Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, Markowitz M. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature. 1995;373(6510):123–6.PubMed

53.

Collier AC, Coombs RW, Schoenfeld DA, et al. Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. AIDS Clinical Trials Group. N Engl J Med. 1996;334(16):1011–7.PubMed

54.

Essex M, Mboup S, Kanki P, Marlink R, Tlou S, editors. AIDS in Africa. New York: Kluwer Academic/Plenum; 2002.

55.

Lu Y, Essex M, editors. AIDS in Asia. New York: Kluwer Academic/Plenum; 2004.

56.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 10.

57.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 169.

58.

Duesberg PH, Rasnick D. The AIDS dilemma: drug diseases blamed on a passenger virus. Genetica. 1998;104:85–132.PubMed

59.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 255–97.

60.

Duesberg PH. Human immunodeficiency virus and acquired immunodeficiency syndrome: correlation but not causation. Proc Natl Acad Sci USA. 1989;86:755–64.PubMed

61.

Duesberg PH. AIDS epidemiology: inconsistencies with human immunodeficiency virus and with infectious disease. Proc Natl Acad Sci USA. 1991;88:1575–9.PubMed

62.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 175.

63.

Duesberg PH. Duesberg defends challenges to the existence of HIV. Continuum. 1996;4(2):8–9.

64.

Duesberg PH. The role of drugs in the origin of AIDS. Biomed Pharmacother. 1992;46:3–15.PubMed

65.

Duesberg PH. Foreign-protein-mediated immunodeficiency in hemophiliacs with and without HIV. Genetica. 1995;95:51–70.PubMed

66.

Allain JP. Transfusion risks of yesterday and of today. Transfus Clin Biol. 2003;10(1):1–5.PubMed

67.

Duesberg P, Koehnlein C, Rasnick D. The chemical bases of the various AIDS epidemics: recreational drugs, anti-viral chemotherapy and malnutrition. J Biosci. 2003;28(4):383–412.PubMed

68.

Kalichman SC. Denying AIDS: conspiracy theories, pseudoscience, and human tragedy. New York and London: Copernicus/Springer; 2009. p. 44.

69.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 184–5.

70.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 187.

71.

Duesberg PH. Inventing the AIDS virus. Washington: Regnery; 1997. p. 419.

72.

UNAIDS. Report on the global HIV/AIDS epidemic. Geneva: UNAIDS; 2008.

73.

Barnhart HX, Caldwell MB, Thomas P, et al. Natural history of human immunodeficiency virus disease in perinatally infected children: an analysis from the Pediatric Spectrum of Disease Project. Pediatrics. 1996;97(5):710–6.PubMed

74.

European Collaborative Study. Children born to women with HIV-1 infection: natural history and risk of transmission. Lancet. 1991;337(8736):253–60.

75.

Newell ML, Borja MC, Peckham C. European Collaborative Study. Height, weight, and growth in children born to mothers with HIV-1 infection in Europe. Pediatrics. 2003;111(1):e52–60.PubMed

76.

UNAIDS. Report on the global HIV/AIDS epidemic. Geneva: UNAIDS; 2000.

77.

Duesberg PH. AIDS acquired by drug consumption and other noncontagious risk factors. Pharmac Ther. 1992;55:201–77.

78.

Msisha WM, Kapiga SH, Earls F, Subramanian SV. Socioeconomic status and HIV seroprevalence in Tanzania: a counterintuitive relationship. Int J Epidemiol. 2008;37(6):1297–303.PubMed

79.

Piot P, Greener R, Russell S. Squaring the circle: AIDS, poverty, and human development. PLoS Med. 2007;4(10):1571–5.PubMed

80.

Begtrup K, Melbye M, Biggar RJ, Goedert JJ, Knudsen K, Andersen PK. Progression to acquired immunodeficiency syndrome is influenced by CD4 T-lymphocyte count and time since seroconversion. Am J Epidemiol. 1997;145(7):629–35.PubMed

81.

Vermund SH, Hoover DR, Chen K. CD4+ counts in seronegative homosexual men. The Multicenter AIDS Cohort Study. N Engl J Med. 1993;328(6):442.PubMed

82.

Des Jarlais DC, Friedman SR, Marmor M, et al. CD4 lymphocytopenia among injecting drug users in New York City. J Acquir Immune Defic Syndr. 1993;6(7):820–2.PubMed

83.

Donegan E, Stuart M, Niland JC, et al. Infection with human immunodeficiency virus type 1 (HIV-1) among recipients of antibody-positive blood donations. Ann Intern Med. 1990;113(10):733–9.PubMed

84.

Hughes SM, Amadi B, Mwiya M, et al. CD4 counts decline despite nutritional recovery in HIV-infected Zambian children with severe malnutrition. Pediatrics. 2009;123(2):e347–51.PubMed

85.

Aina O, Dadik J, Charurat M, et al. Reference values of CD4 T lymphocytes in human immunodeficiency virus-negative adult Nigerians. Clin Diagn Lab Immunol. 2005;12(4):525–30.PubMed

86.

Maclure M. Inventing the AIDS virus hypothesis: an illustration of scientific vs unscientific induction. Epidemiology. 1998;9(4):467–73.PubMed

87.

Cohen J. The Duesberg phenomenon. Science. 1994;266:1642–4.PubMed

88.

Kalichman SC. Denying AIDS: conspiracy theories, pseudoscience, and human tragedy. New York and London: Copernicus/Springer; 2009. p. 9.

89.

Schünemann HJ, Fretheim A, Oxman AD. Improving the use of research evidence in guideline development: 9. Grading evidence and recommendations. Health Res Policy Syst. 2006;4:21.PubMed

90.

Chin R, Lee BY. Principles and practice of clinical trial medicine. London: Academic Press; 2008.

91.

Light RJ, Pillemer DB. Summing up: the science of reviewing research. Cambridge: Harvard University Press; 1984.

92.

Egger M, Davey Smith G, Altman DG, editors. Systematic reviews in health care: meta-analysis in context. 2nd ed. London: BMJ; 2001.

93.

Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup DF. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet. 1999;354(9193):1896–900.PubMed

94.

Chigwedere P, Seage GR, Lee TH, Essex M. Efficacy of antiretroviral drugs in reducing mother-to-child transmission of HIV in Africa: a meta-analysis of published clinical trials. AIDS Res Hum Retroviruses. 2008;24(6):827–37.PubMed

95.

Atkins D, Best D, Briss PA, et al. GRADE Working Group. Grading quality of evidence and strength of recommendations. BMJ. 2004;328(7454):1490.PubMed

96.

Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17(1):1–12.PubMed

97.

Institute of Medicine. Adverse events associated with childhood vaccines: evidence bearing on causality. Washington: National Academy Press; 1993.

98.

Stoto MA. Research synthesis for public health policy: experience of the Institute of Medicine. In: Stangl D, Berry D, editors. Meta-analysis in medicine and health policy. New York: Marcel Dekker; 2000.

99.

Volmink J, Siegfried NL, van der Merwe L, Brocklehurst P. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2007;1:CD003510.PubMed

100.

Suksomboon N, Poolsup N, Ket-Aim S. Systematic review of the efficacy of antiretroviral therapies for reducing the risk of mother-to-child transmission of HIV infection. J Clin Pharm Ther. 2007;32:293–311.PubMed

101.

Bartlett JA, Benoit SL, Johnson VA, et al. Lamivudine plus zidovudine compared with zalcitabine plus zidovudine in patients with HIV infection. A randomized, double-blind, placebo-controlled trial. North American HIV Working Party. Ann Intern Med. 1996;125(3):161–72.PubMed

102.

Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283(4):492–8.PubMed

103.

Darbyshire J, Foulkes M, Peto R, et al. Zidovudine (AZT) versus AZT plus didanosine (ddI) versus AZT plus zalcitabine (ddC) in HIV infected adults. Cochrane Database Syst Rev. 2000;3:CD002038.PubMed

104.

Jordan R, Gold L, Cummins C, Hyde C. Systematic review and meta-analysis of evidence for increasing numbers of drugs in antiretroviral combination therapy. BMJ. 2002;324(7340):757.PubMed

105.

Rutherford G, Sangani P, Kennedy GE. Three- or four- versus two-drug antiretroviral maintenance regimens for HIV infection. Cochrane Database Syst Rev. 2003;3:CD002037.

106.

Siegfried N, van Deventer PJU, Mahomed FA, Rutherford G. Stavudine, lamivudine and nevirapine combination therapy for treatment of HIV infection and AIDS in adults. Cochrane Database Syst Rev. 2006;2:CD004535.PubMed

107.

Humphreys E, Hernandez LB, Rutherford G. Antiretroviral regimens for patients with HIV who fail first-line antiretroviral therapy. Cochrane Database Syst Rev. 2007;4:CD006517.PubMed

108.

Shey M, Kongnyuy EJ, Shang J, Wiysonge CS. A combination drug of abacavir-lamivudine-zidovudine (Trizivir®) for treating HIV infection and AIDS. Cochrane Database Syst Rev. 2009;3:CD005481.PubMed

109.

Djomand G, Roels T, Ellerbrock T, et al. Virologic and immunologic outcomes and programmatic challenges of an antiretroviral treatment pilot project in Abidjan, Cote d’Ivoire. AIDS. 2003;17(Suppl 3):S5–15.PubMedCrossRef

110.

Coetzee D, Hildebrand K, Boulle A, et al. Outcomes after two years of providing antiretroviral treatment in Khayelitsha, South Africa. AIDS. 2004;18(6):887–95.PubMed

111.

Wester CW, Kim S, Bussmann H, et al. Initial response to highly active antiretroviral therapy in HIV-1C-infected adults in a public sector treatment program in Botswana. J Acquir Immune Defic Syndr. 2005;40(3):336–43.PubMed

112.

Etard JF, Ndiaye I, Thierry-Mieg M, et al. Mortality and causes of death in adults receiving highly active antiretroviral therapy in Senegal: a 7-year cohort study. AIDS. 2006;20(8):1181–9.PubMed

113.

Stringer JS, Zulu I, Levy J, et al. Rapid scale-up of antiretroviral therapy at primary care sites in Zambia: feasibility and early outcomes. JAMA. 2006;296(7):782–93.PubMed

114.

Ivers LC, Kendrick D, Doucette K. Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature. Clin Infect Dis. 2005;41(2):217–24.PubMed

115.

Hammond R, Harry TC. Efficacy of antiretroviral therapy in Africa: effect on immunological and virological outcome measures: a meta-analysis. Int J STD AIDS. 2008;19(5):291–6.PubMed

116.

Braitstein P, Brinkhof MW, Dabis F, et al. Antiretroviral therapy in lower income countries (ART-LINC) collaboration; ART cohort collaboration (ART-CC) groups. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–24.PubMed

117.

Preston S, Heuveline P, Guillot M. Demography: measuring and modeling population processes. Oxford: Wiley-Blackwell; 2000. p. 1–20.

118.

Statistics South Africa. Mortality and causes of death in South Africa, 2006: findings from death notification. South Africa: Statistics South Africa; 2008.

119.

Stanecki KA, Walker N. Current estimates and projections for the epidemic. In: Essex M, Mboup S, Kanki P, Marlink R, Tlou S, editors. AIDS in Africa. New York: Kluwer Academic/Plenum; 2002. p. 281–96.

120.

Dorrington R, Bourne D, Bradshaw D, Laubscher R, Timæus I. The impact of HIV/AIDS on adult mortality in South Africa. Burden of Disease Research Unit, Medical Research Council (SA); 2001:10. Available at: <http://www.mrc.ac.za/bod/complete.pdf> . Accessed 2009 Aug 9.

121.

UNAIDS Reference Group on Estimates, Modelling and Projections. Improved methods and assumptions for estimation of the HIV/AIDS epidemic and its impact: recommendations of the UNAIDS Reference Group on Estimates, Modelling and Projections. AIDS. 2002;16(9):W1–14.

122.

Walker N, Stanecki KA, Brown T, et al. Methods and procedures for estimating HIV/AIDS and its impact: the UNAIDS/WHO estimates for the end of 2001. AIDS. 2003;17(15):2215–25.PubMed

123.

Stover J, Johnson P, Zaba B, Zwahlen M, Dabis F, Ekpini RE. The spectrum projection package: improvements in estimating mortality, ART needs, PMTCT impact and uncertainty bounds. Sex Transm Infect. 2008;84(Suppl 1):i24–30.PubMed

124.

Stover J, Ghys PD, Walker N. Testing the accuracy of demographic estimates in countries with generalized epidemics. AIDS. 2004;18(Suppl 2):S67–73.PubMed

125.

Grassly NC, Morgan M, Walker N, et al. Uncertainty in estimates of HIV/AIDS: the estimation and application of plausibility bounds. Sex Transm Infect. 2004;80(Suppl 1):i31–8.PubMed

126.

Walker N, Grassly NC, Garnett GP, Stanecki KA, Ghys PD. Estimating the global burden of HIV/AIDS: what do we really know about the HIV pandemic? Lancet. 2004;363(9427):2180–5.PubMed

127.

Gouws E, Mishra V, Fowler TB. Comparison of adult HIV prevalence from national population-based surveys and antenatal clinic surveillance in countries with generalised epidemics: implications for calibrating surveillance data. Sex Transm Infect. 2008;84(Suppl 1):i17–23.PubMed

128.

Actuarial Society of South Africa. ASSA 2003 AIDS and demographic model. Cape Town: Actuarial Society of South Africa; 2005.

129.

Boerma JT, Nunn AJ, Whitworth JA. Mortality impact of the AIDS epidemic: evidence from community studies in less developed countries. AIDS. 1998;12(Suppl 1):S3–14.PubMed

130.

Blacker J. The impact of AIDS on adult mortality: evidence from national and regional statistics. AIDS. 2004;18(Suppl 2):S19–26.PubMed

131.

Stover J, Way P. Projecting the impact of AIDS on mortality. AIDS. 1998;12(Suppl 1):S29–39.PubMed

132.

The Durban Declaration. Nature 2000;406:15–6.

133.

Horton R. African AIDS beyond Mbeki: tripping into anarchy. Lancet. 2000;356(9241):1541–2.PubMed

134.

Kalichman SC. Denying AIDS: conspiracy theories, pseudoscience, and human tragedy. New York and London: Copernicus/Springer; 2009. p. 8–13.

135.

Cameron E. Witness to AIDS. London: I. B. Tauris; 2005.

136.

Moore JP. The dangers of denying HIV. Nature. 2009;459:168.

137.

Geffen N. Justice after AIDS denialism: should there be prosecutions and compensation? J Acquir Immune Defic Syndr. 2009;51(4):454–5.PubMed

138.

Wainberg M. In: Scovill R. The other side of AIDS (film); 2004. Available at: http://www.theothersideofaids.com/free_to_question.html. Accessed 2009 Nov 27.

139.

Muga W. When public negligence can become criminal. African Business 2009 May.

140.

Moore JP, Bergman J, Wainberg MA. The AIDS denialists are still around. IAS Newsl. 2007:4–5.

141.

Chigwedere PM. Antiretroviral drug use in South Africa: from science to practice and malpractice (Dissertation). Boston: Harvard School of Public Health; 2008.

Title: AIDS Denialism and Public Health Practice
Authors: Pride Chigwedere
M. Essex
Publication date: 01-04-2010
Publisher: Springer US
Published in: AIDS and Behavior / Issue 2/2010
Print ISSN: 1090-7165
Electronic ISSN: 1573-3254
DOI: https://doi.org/10.1007/s10461-009-9654-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2010

Cognitive Adaptability as a Moderator of Expressive Writing Effects in an HIV Sample

Mental Health Considerations in Secondary HIV Prevention

Stress Biomarkers as Outcomes for HIV+ Prevention: Participation, Feasibility and Findings Among HIV+ Latina and African American Mothers

Integrating HIV Prevention into Services for Abused Women in South Africa

Population Levels of Psychological Stress, Herpesvirus Reactivation and HIV

HIV-Infected Prison Inmates: Depression and Implications for Release Back to Communities

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials